AOD-9604 Mental Health and Mood Impact: What the Evidence Actually Shows

What Is AOD-9604 and Why Does the Mental Health Question Arise?

AOD-9604 is a stabilized synthetic peptide corresponding to amino acids 176 through 191 of the C-terminal region of human growth hormone. Researchers at Monash University isolated this fragment specifically because it retained the fat-mobilizing properties of native GH without stimulating the GH receptor in a way that raises IGF-1 or promotes cell proliferation. The mental health question arises because patients and prescribers conflate it with full GH therapy, growth hormone secretagogues such as sermorelin or ipamorelin, and the broad category of "peptide therapy", all of which have different CNS profiles.

The Mechanism That Separates AOD-9604 From GH

Native growth hormone exerts well-documented central nervous system effects. GH receptors are expressed in the hippocampus, hypothalamus, and cortex, and GH administration in GH-deficient adults improves measures of psychological well-being, vitality, and cognitive speed, largely through IGF-1-mediated signaling 1.

AOD-9604 does not replicate this. Heffernan et al. Demonstrated in diet-induced obese mice that daily subcutaneous injection of AOD-9604 for 19 days produced significant reductions in body weight and fat mass without any measurable increase in serum IGF-1, and without the cartilage and organ growth seen with full-length GH 1. The peptide appears to act primarily on beta-3 adrenergic receptors in adipocytes, promoting lipolysis through a pathway that bypasses the GH receptor entirely 1.

Why That Mechanism Matters for Mood

If IGF-1 elevation is the primary driver of the mood and cognitive benefits reported with GH replacement therapy, then AOD-9604's failure to raise IGF-1 means patients should not expect those same neuropsychiatric benefits. This is not a safety concern, it is a realistic expectation-setting point that any prescribing clinician should communicate clearly before initiating a compounding protocol.

The Direct Evidence Gap: No Published Mood RCTs

No randomized controlled trial has measured anxiety, depression scores, mood lability, cognitive performance, or quality-of-life psychiatric subscales as primary or secondary endpoints in humans receiving AOD-9604. This is the central clinical reality. The available human data were generated primarily during the early 2000s by Metabolic Pharmaceuticals, which filed an Investigational New Drug application and ran Phase IIb trials for obesity. Those trials assessed body composition and metabolic endpoints. Psychiatric outcomes were not systematically collected 2.

What the Obesity Trials Did Measure

The Phase IIb dose-ranging study in overweight adults (doses of 1 mg, 5 mg, 10 mg, and 20 mg oral AOD-9604 daily for 12 weeks) measured body weight, fat mass by DEXA, fasting glucose, lipids, and standard safety labs including liver enzymes and complete blood count 2. Adverse event reporting followed standard pharmaceutical trial conventions, patients were asked about treatment-emergent adverse events at each visit, and nausea, headache, and injection-site reactions were among the most commonly reported issues. Mood-related adverse events were not reported at frequencies that reached statistical threshold in published summaries, but the trials were not powered or designed to detect them.

What "No Evidence" Actually Means Clinically

Absence of evidence is not the same as evidence of absence. The obesity trials enrolled several hundred participants over periods of 12 to 24 weeks. Psychiatric side effects with a true incidence below 2 to 3 percent would likely have been missed given those sample sizes. A drug exerting beta-adrenergic activity, even peripherally, could plausibly produce transient anxiety, palpitations, or sleep disruption in a minority of sensitive patients. These are not theoretical concerns. Beta-adrenergic stimulation at any receptor subtype carries acknowledged CNS-adjacent effects, and the FDA's pharmacology review framework for adrenergic agents routinely flags anxiety and insomnia as signals to monitor 3.

Proposed Indirect Pathways: How AOD-9604 Could Affect Mood

Even without direct CNS receptor activity, AOD-9604 may influence mood through several indirect routes. The evidence for each pathway ranges from mechanistically plausible to speculative, and clinicians should treat them accordingly.

Body Composition Changes and Psychological Well-Being

Fat loss itself has documented effects on psychological well-being independent of the drug that produces it. A meta-analysis of 27 weight-loss intervention trials (N = 3,099 pooled) found that clinically meaningful fat reduction, defined as 5 percent or more of initial body weight, was associated with significant improvements in depression inventory scores, self-reported energy, and body image satisfaction 4. If AOD-9604 produces meaningful fat loss in a given patient, a secondary improvement in mood is biologically plausible through that route alone.

This matters for protocol design. A patient who reports feeling "better" on AOD-9604 may be experiencing the well-established psychological benefits of adipose reduction rather than any direct neuropsychiatric action of the peptide. Clinicians attributing mood improvement to AOD-9604 itself, rather than to the resulting body composition change, would be over-attributing.

Beta-3 Adrenergic Receptor Activity and the Gut-Brain Axis

Beta-3 adrenergic receptors are expressed not only in white adipose tissue but also in the gastrointestinal tract and, at lower densities, in bladder and brown adipose tissue. The relationship between gut motility, gut-brain signaling, and mood is increasingly well-documented. Altered gut motility from any adrenergic intervention could theoretically modulate serotonin availability, roughly 90 percent of the body's serotonin is synthesized in enterochromaffin cells of the intestinal mucosa 5. This remains a hypothesis. No study has measured intestinal serotonin turnover in response to AOD-9604.

Sleep Architecture and Growth Hormone Pulsatility

Endogenous growth hormone is secreted predominantly during slow-wave sleep, and disruptions to GH pulsatility correlate with impaired sleep architecture and worsened mood scores in healthy adults 6. AOD-9604 does not stimulate endogenous GH secretion and does not act as a secretagogue, so it would not be expected to amplify or disrupt nocturnal GH pulses. However, patients sometimes combine AOD-9604 with CJC-1295, ipamorelin, or other secretagogues in multi-peptide protocols. In those combination contexts, sleep effects observed clinically are more likely attributable to the secretagogue component than to AOD-9604 itself.

Cortisol, Stress Response, and Adipokine Remodeling

Does AOD-9604 Affect Cortisol?

No published study has measured cortisol in response to AOD-9604 administration in humans. Full-length GH suppresses cortisol-binding globulin and can modulate HPA axis reactivity, but this effect is mediated through GH-receptor activation. Because AOD-9604 bypasses the GH receptor 1, the cortisol-modulating effects of native GH are not expected to apply. In animal models examining GH fragment activity, no HPA axis disruption was reported 1.

Adipokines, Leptin, and Mood

Adipose tissue is an endocrine organ. As visceral fat decreases, concentrations of pro-inflammatory adipokines, particularly TNF-alpha and IL-6, tend to fall, while adiponectin concentrations tend to rise 7. Chronic low-grade inflammation driven by visceral adiposity is independently associated with depressive symptom burden: a large prospective cohort study (N = 14,828) found that each standard-deviation increase in IL-6 was associated with a 1.32-fold increased odds of depressive symptoms at 10-year follow-up 8. If AOD-9604 reduces visceral adiposity and secondarily reduces inflammatory cytokine output, a downstream improvement in mood is biologically plausible, but this chain of inference requires verification at each step.

What Compounding Patients Actually Report: Clinical Observations

No peer-reviewed publication has systematically catalogued patient-reported mental health outcomes for compounded AOD-9604. The observations summarized here come from clinical practice patterns reported in the hormone-therapy prescribing community and should be interpreted as preliminary clinical signals, not evidence.

Patients on subcutaneous AOD-9604 protocols (typical dose range: 250 mcg to 300 mcg once daily, administered in the morning on a fasted stomach) most commonly report:

• Improved energy and motivation, typically noted within 2 to 4 weeks, more likely tied to early fat mobilization and the psychological effect of body composition progress than to a direct CNS mechanism.
• Mild, transient anxiety or restlessness in the first 7 to 14 days, consistent with the beta-adrenergic activity of the peptide and most commonly self-limiting without dose adjustment.
• No significant change in sleep onset or sleep quality when AOD-9604 is used as a standalone agent, which aligns with its lack of secretagogue activity.
• Mood disruption in a small minority of patients, characterized by irritability rather than depression, when AOD-9604 is combined with caloric restriction protocols below 1,000 kcal per day, where hypocaloric stress itself is the more parsimonious explanation.

Prescribers at our affiliated practices use a standardized baseline PHQ-9 and GAD-7 screen before initiating any peptide protocol, with repeat scores at 4 weeks and 12 weeks. This is not required by any current guideline but represents reasonable clinical practice given the uncharacterized psychiatric profile of novel compounded peptides.

Regulatory Context and Prescribing Framework

AOD-9604 is not FDA-approved as a finished pharmaceutical product. Metabolic Pharmaceuticals' obesity indication did not proceed to Phase III. In the United States, it is dispensed by 503A compounding pharmacies under a physician prescription when prescribed for an identified patient with a legitimate medical need, typically adipose modulation or metabolic optimization protocols 9.

The FDA has not issued a specific prohibition on 503A compounding of AOD-9604 as of this writing, but the regulatory field for peptide compounds changed meaningfully after the FDA's 2023 and 2024 guidance updates addressing bulk peptide substances under 503A and 503B authorities 9. Prescribers should verify current status with their compounding pharmacy before initiating protocols.

Informed Consent Considerations for Mental Health

Given the absence of published psychiatric outcome data, informed consent for AOD-9604 should explicitly acknowledge:

1. No RCT evidence exists for mood or anxiety effects in either direction.
2. Beta-adrenergic activity may produce transient anxiety or palpitations in sensitive patients.
3. Any mood improvement observed during therapy may reflect body composition changes rather than a direct drug effect.
4. Patients with pre-existing anxiety disorders, bipolar spectrum conditions, or active major depression should have psychiatric status stabilized before adding any novel adrenergic peptide agent.

The Endocrine Society's clinical practice guideline on GH therapy in adults states that "quality of life, including mood and psychological well-being, should be assessed with validated instruments before and during treatment" 10. While this guideline addresses GH replacement rather than AOD-9604 specifically, the monitoring principle applies by reasonable clinical extrapolation.

Comparing AOD-9604 to Other Peptides: Mood Profile Differences

Versus GH Secretagogues (Ipamorelin, Sermorelin, CJC-1295)

GH secretagogues stimulate endogenous GH release, raise IGF-1 over time, and have a more documented (though still incompletely characterized) CNS profile. Patients on ipamorelin-based protocols frequently report improvements in sleep quality, mood, and motivation, an effect plausibly mediated through GH-stimulated IGF-1 acting on hippocampal neurons 6. AOD-9604 alone would not be expected to produce these effects because it does not raise IGF-1 1.

Versus GLP-1 Receptor Agonists

Semaglutide and tirzepatide both have emerging CNS data. The STEP-1 trial (N = 1,961) showed 14.9 percent mean weight loss at 68 weeks with semaglutide 2.4 mg versus 2.4 percent with placebo, and secondary analyses of that trial detected improvements in patient-reported outcome measures including physical functioning and cardiometabolic quality of life 11. GLP-1 receptors are expressed in the brainstem, hypothalamus, and limbic system, giving semaglutide a direct CNS mechanism that AOD-9604 lacks. The two drug classes are not directly comparable for mental health purposes.

Versus BPC-157

BPC-157 is a gastric peptide fragment with a more directly proposed neuromodulatory mechanism. Animal studies have shown BPC-157 affects dopaminergic and serotonergic pathways 12. AOD-9604 has no comparable preclinical neurochemistry data. Patients seeking peptide therapy specifically for mood indications have more theoretical support for BPC-157 than for AOD-9604 in the current literature, though neither has strong human psychiatric trial data.

Monitoring Protocol: A Practical Clinical Framework

For clinicians prescribing AOD-9604 in a 503A compounding context, the following monitoring approach is aligned with the absence-of-evidence reality while meeting reasonable duty-of-care standards.

Baseline (before first dose):

• PHQ-9 and GAD-7 questionnaires
• Review of current psychiatric medications, noting any agents with adrenergic activity (stimulants, SNRIs, bupropion)
• Blood pressure and resting heart rate
• Fasting glucose and HbA1c (given AOD-9604's metabolic mechanism)

Week 4 check-in:

• Repeat PHQ-9 and GAD-7
• Patient-reported sleep quality (single-item or Pittsburgh Sleep Quality Index)
• Inquiry about palpitations, restlessness, or mood lability
• Weight and waist circumference for body composition progress documentation

Week 12 evaluation:

• Full repeat of baseline labs
• Document any psychiatric adverse events formally in the medical record
• Consider discontinuation if GAD-7 score has increased by 5 or more points from baseline without a clear independent explanation

A patient whose GAD-7 score rises from 4 at baseline to 9 at week 4 on AOD-9604 monotherapy, with no change in life stressors, sleep, or concurrent medications, warrants serious consideration of dose reduction or discontinuation, even in the absence of a proven causal mechanism.

Key Takeaways for Prescribers and Patients

AOD-9604 is a lipolytic peptide with a well-characterized mechanism in adipose tissue and no demonstrated direct central nervous system activity. Heffernan et al. (2001) confirmed the IGF-1-sparing mechanism that separates it from native GH 1, and no published RCT has measured its psychiatric effects in either direction 2. Mood improvements reported by patients on AOD-9604 protocols are most parsimoniously explained by fat loss and its downstream psychological effects, not by direct neuropsychiatric action of the peptide.

Prescribers should use validated mood screening tools at baseline and at 4-week intervals, document informed consent that explicitly acknowledges the absence of psychiatric outcome data, and maintain a low threshold for reassessment if anxiety or mood lability emerges during the first 30 days of therapy.

Any patient with a GAD-7 score of 10 or higher at baseline should have anxiety addressed as a primary clinical priority before a novel adrenergic peptide compound is introduced.